Skip to main content

Biotech ETFs Could Be in for More Pain Ahead

After suffering one of their worst Aprils in years, biotech sector-related exchange traded funds could be in for even more pain ahead. Year-to-date, the SPDR S&P Biotech ETF (NYSEArca: XBI) has declined 32.2% and the iShares Nasdaq Biotechnology ETF (IBB), the largest biotech-related ETF by...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.